Tvardi Therapeutics, Inc. — Form 8-K
Filed July 7, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Tvardi announced Phase 1 results for TTI-109, a phosphate prodrug of its STAT3 inhibitor TTI-101. The study (three-part design, n=32 in MAD cohort) confirmed rapid conversion to TTI-101 within 2 hours at 95% efficiency, dose-proportional pharmacokinetics with exposures above STAT3 IC₅₀, and exploratory pharmacodynamic data showing up to 60% reductions in disease-relevant immune cell populations (Th17, Tfh, B cells). Critically, diarrhea duration with TTI-109 was substantially shorter (0.46 days) versus TTI-101 (3.35 days) at near-equivalent doses. Company plans Phase 2 trials in dermatologic and GI diseases, contingent on IND clearance and additional funding. Cash position: $25.0M; runway extends to Q4 2026.
Why this rating
Phase 1 validation of lead prodrug candidate de-risks mechanism and improves tolerability profile. Meaningful for clinical advancement but company size and funding dependency limit near-term trajectory impact.
See more from July 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.